Home LiteratureArticle Details
PMID: 20126477 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment.

Neoplasia (New York, N.Y.) ·Vol. 12 ·No. 2 ·2010-02-00 ·Pages 192-205

Morrissey C, Brown LG, Pitts TE, Vessella RL, Corey E

Abstract

Bone morphogenetic protein (BMP) signaling is important in prostate development and prostate cancer (PCa) progression. However, because of the multiple effects of different BMPs, no final conclusions have been made as to the role of BMPs in PCa. In our studies, we have focused on BMP-7 because it is involved in prostate morphogenesis, and its expression is regulated by androgens. The objective of our study was to determine BMP-7 expression in PCa metastases and investigate the effects of BMP-7 on PCa cells. Our results show that BMP-7 is expressed in metastatic PCa and its levels are increased in castration-resistant PCa versus androgen-dependent PCa, whereas the expression of BMP-7 is decreased in primary PCa versus normal prostate. Our in vitro results show that BMP-7 inhibits proliferation of androgen-sensitive LNCaP cells, stimulates androgen receptor signaling, increases the expression of differentiation-associated genes, and decreases the levels of some wingless-regulated transcripts. Interestingly, these effects were not detected in C4-2 castration-resistant PCa cells. In vivo expression of BMP-7 in castration-resistant C4-2 cells did not alter proliferation when these cells were grown subcutaneously, but their growth was inhibited in the bone environment. In summary, our results show that BMP-7 is expressed at the highest level in advanced castration-resistant PCa cells and that the inhibitory effects of BMP-7 are dependent on the differentiation status of PCa cells and the tumor microenvironment. Further studies are needed to identify changes in BMP-7 signaling that lead to the loss of its control of proliferation during PCa progression.

MeSH Terms
Animals Blotting, Western Bone Morphogenetic Protein 7/genetics,metabolism Cell Differentiation/genetics Cell Line, Tumor Gene Expression Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans Immunohistochemistry Immunoprecipitation Male Mice Mice, SCID Neoplasm Metastasis/pathology Neoplasms, Hormone-Dependent/metabolism,pathology Phenotype Prostatic Neoplasms/genetics,metabolism,pathology Receptors, Androgen/metabolism Reverse Transcriptase Polymerase Chain Reaction Transfection
Chemicals
BMP7 protein, human Bone Morphogenetic Protein 7 Receptors, Androgen
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Morrissey Colm
Department of Urology, University of Washington, Seattle, WA 98195, USA.
Brown Lisha G
Pitts Tiffany E M
Vessella Robert L
Corey Eva
References (54)
54 references, click to expand
  1. HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells.
    Urol Oncol. 2008 Mar-Apr;26(2):190-7 PMID: 18312940
  2. The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3.
    J Biol Chem. 2002 Jan 11;277(2):1240-8 PMID: 11707452
  3. The Wnt signaling pathway in development and disease.
    Annu Rev Cell Dev Biol. 2004;20:781-810 PMID: 15473860
  4. Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins.
    J Cell Biochem. 2007 Nov 1;102(4):829-39 PMID: 17914743
  5. Wnt signalling and prostate cancer.
    Prostate Cancer Prostatic Dis. 2005;8(2):119-26 PMID: 15809669
  6. Prostate cancer cells promote osteoblastic bone metastases through Wnts.
    Cancer Res. 2005 Sep 1;65(17):7554-60 PMID: 16140917
  7. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer.
    Prostate. 2003 Mar 1;54(4):268-74 PMID: 12539225
  8. Androgen-dependent gene expression of bone morphogenetic protein 7 in mouse prostate.
    Prostate. 1998 Dec 1;37(4):236-45 PMID: 9831220
  9. A novel bone morphogenetic protein signaling in heterotypic cell interactions in prostate cancer.
    Cancer Res. 2008 Jan 1;68(1):198-205 PMID: 18172312
  10. Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer.
    Croat Med J. 2005 Jun;46(3):389-96 PMID: 15861517
  11. Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases.
    Cancer Treat Res. 2004;118:311-39 PMID: 15043198
  12. Cross-talk between Wnt and bone morphogenetic protein 2 (BMP-2) signaling in differentiation pathway of C2C12 myoblasts.
    J Biol Chem. 2005 Nov 11;280(45):37660-8 PMID: 16150699
  13. The effect of leukemia inhibitory factor on bone in vivo.
    Endocrinology. 1993 Mar;132(3):1359-66 PMID: 8440191
  14. Discordant protein and mRNA expression in lung adenocarcinomas.
    Mol Cell Proteomics. 2002 Apr;1(4):304-13 PMID: 12096112
  15. When prostate cancer meets bone: control by wnts.
    Cancer Lett. 2007 Aug 18;253(2):170-9 PMID: 17462819
  16. Characterization of C4-2 prostate cancer bone metastases and their response to castration.
    J Bone Miner Res. 2003 Oct;18(10):1882-8 PMID: 14584899
  17. Expression of bone morphogenetic protein-7 (BMP-7) in human prostate.
    Prostate. 2004 Apr 1;59(1):101-6 PMID: 14991870
  18. Roles and regulation of Wnt signaling and beta-catenin in prostate cancer.
    Cancer Lett. 2006 Jun 8;237(1):22-32 PMID: 16023783
  19. [Molecular aspects of prostate cancer: recent data from the literature].
    Bull Cancer. 2007 Jul;94(7 Suppl):F77-88 PMID: 17845997
  20. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
    J Bone Miner Res. 2005 Dec;20(12):2189-99 PMID: 16294272
  21. Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor.
    Cancer Res. 2004 Nov 1;64(21):7918-26 PMID: 15520198
  22. Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines.
    Int J Oncol. 2005 Apr;26(4):1033-40 PMID: 15753999
  23. Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes.
    Neoplasia. 2006 Oct;8(10):862-78 PMID: 17032503
  24. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
    Cancer Res. 2008 Jun 1;68(11):4447-54 PMID: 18519708
  25. Modifications of the Goldner and Gomori one-step trichrome stains for plastic-embedded thin sections of bone.
    Am J Med Technol. 1977 Jun;43(6):536-8 PMID: 69401
  26. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know?
    Endocr Rev. 2005 Dec;26(7):898-915 PMID: 16126938
  27. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists.
    J Urol. 2007 Sep;178(3 Pt 1):1086-91 PMID: 17644136
  28. Linking beta-catenin to androgen-signaling pathway.
    J Biol Chem. 2002 Mar 29;277(13):11336-44 PMID: 11792709
  29. Bone morphogenetic protein-2 modulates Wnt and frizzled expression and enhances the canonical pathway of Wnt signaling in normal keratinocytes.
    J Dermatol Sci. 2006 May;42(2):111-9 PMID: 16442268
  30. Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer.
    Cancer Genet Cytogenet. 2007 Jul 15;176(2):161-5 PMID: 17656261
  31. Control of prostate cell growth: BMP antagonizes androgen mitogenic activity with incorporation of MAPK signals in Smad1.
    EMBO J. 2007 Jan 24;26(2):346-57 PMID: 17183365
  32. Bone morphogenetic protein 7 protects prostate cancer cells from stress-induced apoptosis via both Smad and c-Jun NH2-terminal kinase pathways.
    Cancer Res. 2006 Apr 15;66(8):4285-90 PMID: 16618753
  33. BMP7 influences proliferation, migration, and invasion of breast cancer cells.
    Cancer Lett. 2009 Mar 8;275(1):35-43 PMID: 18980801
  34. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Bone. 2006 Feb;38(2):154-66 PMID: 16126463
  35. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.
    Cancer. 2004 Sep 15;101(6):1345-56 PMID: 15316903
  36. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone.
    Hum Pathol. 2003 Jul;34(7):646-53 PMID: 12874759
  37. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.
    Prostate. 2010 Mar 1;70(4):412-24 PMID: 19866469
  38. Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells.
    Oncogene. 2006 Jun 8;25(24):3436-44 PMID: 16474850
  39. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo.
    Am J Pathol. 2007 Sep;171(3):1047-57 PMID: 17724140
  40. Characterization and expression of a cDNA encoding the human androgen receptor.
    Proc Natl Acad Sci U S A. 1989 Jan;86(1):327-31 PMID: 2911578
  41. Bone morphogenetic protein signaling in prostate cancer cell lines.
    J Cell Biochem. 2004 Jan 1;91(1):151-60 PMID: 14689587
  42. Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases.
    BMC Cancer. 2007 Aug 03;7:148 PMID: 17683568
  43. Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells.
    Cancer Res. 2005 Jul 1;65(13):5769-77 PMID: 15994952
  44. Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer.
    Genes Chromosomes Cancer. 2006 Apr;45(4):411-9 PMID: 16419056
  45. Novel function of androgen receptor-associated protein 55/Hic-5 as a negative regulator of Smad3 signaling.
    J Biol Chem. 2005 Feb 18;280(7):5154-62 PMID: 15561701
  46. Bone morphogenetic protein 7 expression associates with bone metastasis in breast carcinomas.
    Ann Oncol. 2008 Feb;19(2):308-14 PMID: 17895257
  47. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function.
    Prostate. 2003 Jun 15;56(1):13-22 PMID: 12746842
  48. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer.
    J Cell Biochem. 2006 Oct 1;99(2):402-10 PMID: 16741972
  49. Induction of cell-free, in vitro transcription by recombinant androgen receptor peptides.
    J Steroid Biochem Mol Biol. 1996 Nov;59(3-4):243-50 PMID: 9010316
  50. Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer.
    Neoplasia. 2005 Mar;7(3):207-23 PMID: 15799821
  51. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis.
    Oncogene. 2003 Aug 28;22(36):5602-13 PMID: 12944908
  52. Bone morphogenetic protein 6 (BMP6) and BMP7 inhibit estrogen-induced proliferation of breast cancer cells by suppressing p38 mitogen-activated protein kinase activation.
    J Endocrinol. 2008 Dec;199(3):445-55 PMID: 18780779
  53. Bone morphogenetic protein-2 induces hypophosphorylation of Rb protein and repression of E2F in androgen-treated LNCaP human prostate cancer cells.
    Int J Mol Med. 2005 Feb;15(2):253-8 PMID: 15647840
  54. Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues.
    Cancer Res. 2000 Jun 1;60(11):2840-4 PMID: 10850425
Article Info
Journal
Neoplasia (New York, N.Y.)
Abbr.
Neoplasia
ISSN
1476-5586
Published
2010-02-00
Pages
192-205
Language
English
Region
United States
NLM ID
100886622
PMCID
PMC2814357
Subset
IM
Grants
NCI NIH HHS · P50 CA097186 · United States
NCI NIH HHS · R01 CA125395-04 · United States
NCI NIH HHS · P01 CA085859 · United States
NCI NIH HHS · P01CA085859 · United States
NCI NIH HHS · 5R01CA125395 · United States
NCI NIH HHS · P50CA097186 · United States
NCI NIH HHS · R01 CA125395 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com